Overview

An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This noninterventional, open-label study will observe the safety and tolerability of peginterferon alfa-2a in combination with ribavirin among Austrian participants treated for HCV infection according to routine practice.
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Interferon-alpha
Peginterferon alfa-2a
Ribavirin